|Bid||18.18 x 800|
|Ask||19.55 x 1000|
|Day's Range||18.42 - 19.06|
|52 Week Range||10.30 - 27.00|
|Beta (3Y Monthly)||3.47|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 6, 2018 - Aug 10, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||39.75|
Omeros Corporation (OMER) today announced the recent presentation of a case report describing resolution of gastrointestinal hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) following narsoplimab treatment under a compassionate-use protocol. The case was presented at the 2019 Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) held March 24-27 in Frankfurt, Germany. Omeros is reporting the case to ensure broad availability of the information presented.
Omeros Corporation (OMER) today announced an upcoming educational event at the 2019 Annual Meeting of the European Society of Blood and Marrow Transplantation to be held in Frankfurt, Germany on March 24-27, 2019. Sponsored by Omeros, the educational session entitled “How Do I … Diagnose HSCT-TMA” will be held on Tuesday, March 26, at 2:00-3:30 PM local time. There is growing recognition that hematopoietic stem-cell transplant-associated thrombotic microangiopathy (HSCT-TMA), a potentially lethal complication of stem-cell transplants, is underdiagnosed in the U.S. and worldwide.
Omeros Corporation (OMER), today announced that the company will issue its fourth quarter and year-end 2018 financial results for the period ended December 31, 2018, on Friday, March 1, 2019, before the market opens. Omeros management will host a conference call and webcast that day at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time) to discuss the financial results.
NEW YORK, Feb. 22, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Omeros Corporation today announced that, as the company prepares for planned commercialization of OMS721, the United States Adopted Names Council, in consultation with the World Health Organization’s International Nonproprietary Names Expert Committee, has selected for the drug the nonproprietary name “narsoplimab.” Narsoplimab is the company’s lead human monoclonal antibody targeting mannan-binding ...
Omeros Corporation (OMER) today announced that, based on a recent meeting with the U.S. Food and Drug Administration (FDA), the company has streamlined the required work and further advanced its preparations for its Biologics License Application (BLA) for OMS721 in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA). OMS721 is the company’s Phase 3 human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system.
Omeros Corporation (OMER) today announced the appointment of Thomas F. Bumol, Ph.D., to its Board of Directors. Dr. Bumol is Executive Director of the recently established Allen Institute for Immunology and former longtime senior executive at Eli Lilly and Company.
A look at the shareholders of Omeros Corporation (NASDAQ:OMER) can tell us which group is most powerful. Insiders often own a large chunk of younger, smaller, companies while huge companies Read More...
IgA nephropathy is a kidney disease resulting from the accumulation of an antibody called immunoglobin A in the kidney, which causes inflammation and in turn impacts the ability of the kidney to filter wastes from blood. Following a meeting with the FDA on the Phase 3 trial, Omeros said Thursday it has finalized its clinical plan for OMS721. The company said the FDA agreed to extend the primary endpoint of the assessment of proteinuria from 24 weeks to 36 weeks to allow additional dosing if warranted.
Omeros Corporation (OMER) today announced that it has finalized its clinical plan for OMS721 submission and approval in immunoglobulin A nephropathy (IgAN) following a recent meeting with the U.S. Food and Drug Administration (FDA). OMS721 is Omeros’ lead human monoclonal antibody targeting MASP-2, the effector enzyme of the complement system’s lectin pathway. There is no approved treatment for IgA nephropathy.
Omeros Corporation (OMER), today announced unaudited preliminary revenue results for the fourth quarter ended December 31, 2018. Omeros’ preliminary (unaudited) total and OMIDRIA® (phenylephrine and ketorolac intraocular solution) 1% / 0.3% revenues for the fourth quarter of 2018 are expected to be a record high at approximately $22.0 million compared to $4.6 million in 3Q 2018 and $13.8 million in the prior year fourth quarter. The increase from the prior periods reflects strong demand for OMIDRIA from ambulatory surgery centers (ASCs) and hospitals following reinstatement of pass-through reimbursement for OMIDRIA on October 1, 2018.
NEW YORK, Jan. 03, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Omeros Corporation (OMER) announced today the formation of an independent Academic Leadership Committee (ALC) to support its Phase 3 clinical program for OMS721 in immunoglobulin A (IgA) nephropathy. The committee includes renowned leaders in nephrology and clinical research who will provide clinical guidance to Omeros as it advances its ongoing IgA nephropathy Phase 3 clinical trial ARTEMIS-IGAN.
Omeros Corporation (OMER) today announced that it has entered into a research collaboration with the University of Cambridge, establishing the Omeros Center at Cambridge for Complement and Inflammation Research (OC3IR). The OC3IR currently is focusing on research related to OMS721, Omeros’ lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the complement system’s lectin pathway, and to OMS906, Omeros’ lead human monoclonal antibody targeting MASP-3, the key activator of the complement system’s alternative pathway.
– EMA Confirmed OMS721 Eligibility for European Centralized Marketing Authorization Application Review –
Omeros Corporation (OMER) today announced that it hired two new senior management team members – Daniel Kirby as vice president and head of commercial and Justin McCue, Ph.D. as vice president of chemistry, manufacturing and controls (CMC). OMIDRIA is the company’s marketed drug and the only product of its kind for cataract and lens replacement surgery.
NEW YORK, Nov. 30, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Gregory Demopulos has been the CEO of Omeros Corporation (NASDAQ:OMER) since 1994. This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. Next, we’ll Read More...
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Nov. 8) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) AstraZeneca ...